Endo Announces Issuance of Vasostrict® Patent
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
Go back to Endo Announces Issuance of Vasostrict® Patent
June 28, 2016 3:20 PM EDT
Deutsche Bank maintained a Buy rating on Endo International plc (NASDAQ: ENDP) with a price target of $30. Earlier the company announced that one of its operating companies, Par Pharmaceutical, was issued a new patent relating to Vasostrict 20 units/mL. Analyst
Gregg Gilbert said this was an important development and could help protect a key franchise.
"Vasostrict is a ~$300mn drug (~8% of total revenue), and risk... More
June 28, 2016 2:17 PM EDT
Leerink Partners analyst Jason Gerberry weighed in on Endo International plc (NASDAQ: ENDP) after the company received issuance of US patent #9,375,478, which according to the analyst, at a minimum adds a few year to the firm's Vasostrict exclusivity assumption. While the bull case includes possible major price revision and significantly longer exclusivity,... More
June 28, 2016 1:23 PM EDT
Mizuho analyst Irina Koffler weighed in on Endo Int'l (NASDAQ: ENDP) after the company announced that Vasostrict patent (9,375,478) that expires in Jan 2035, and has been submitted to FDA's Orange Book.
Koffler notes the drug represents approximately $300M in revenues to Endo,... More
June 28, 2016 12:50 PM EDT
Endo Int'l (NASDAQ: ENDP) is surging 17% after the company announced that one of its operating... More
